Search results
Found 30 matches for
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
Young people's development in adversity and delivering effective interventions
Anxiety Brain Depression HIV Neuroimaging PTSD Parenting Refugees and asylum seekers Treatment trials
The research is predominantly concerned with the development of children and adolescents in the face of adversity. There are two objectives. The first has been to elucidate the environmental mechanisms underlying development in adversity. The second has been to use this understanding to develop interventions to enhance children’s and young people's development and support their families.